CAR-T for NHL: a first real-world study

A Clinician's Perspective on Cancer Drug DevelopmentПодробнее

The value of real-world data in the CAR-T fieldПодробнее

Real-world experiences with toxicity in patients treated with CAR-T cell therapyПодробнее

Updates on CAR-T therapies in NHL: real-world data, trials & new indicationsПодробнее

CAR T-cells in lymphoma: new advances and practical aspectsПодробнее

Who Should Receive CAR-T Cell Therapy for Lymphoma?Подробнее

Real world data: CAR T-cell therapy for hematological cancersПодробнее

CAR T-Cell Therapy in Real Practice: Optimizing Referral and Treatment of Patients With NHLПодробнее

The value of real-world data in the CAR-T fieldПодробнее

Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCLПодробнее

Real-world data on axi-cel for patients with large B-cell lymphomaПодробнее

New Models for NHL Care: Innovative Therapy in FL and DLBCLПодробнее

Real-world efficacy & safety data: CAR-T in DLBCLПодробнее

CAR-T for lymphoma: new targets, real world data & resistanceПодробнее

Real-world data on CAR-T therapy for B-ALLПодробнее

Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-cell therapyПодробнее

Medicare Patients Receiving CAR T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World LookПодробнее

CAR T-Cell Therapy: Real-World ApplicationsПодробнее

Investigating the efficacy of CD20 CAR-T cell therapy for WM and CNS lymphomaПодробнее

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cellsПодробнее